NivolumabImmune-mediated hepatitis: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2020年 / 1789卷 / 1期

关键词：

D O I：

10.1007/s40278-020-74545-z

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：195 / 195

相关论文

共 50 条

[21] Ipilimumab/nivolumabImmune-mediated cholangitis : case report
Reactions Weekly, 2024, 2021 (1) : 269 - 269
[22] NivolumabImmune-mediated colitis and lack of efficacy: case report
Reactions Weekly, 2022, 1902 (1) : 347 - 347
[23] Ipilimumab/nivolumabImmune-mediated granulomatous pneumonitis: case report
Reactions Weekly, 2020, 1808 (1) : 158 - 158
[24] NivolumabImmune-mediated lichen ruber pemphigoides: case report
Reactions Weekly, 2018, 1733 (1) : 260 - 260
[25] NivolumabImmune-mediated pneumonia and lack of efficacy: case report
Reactions Weekly, 2025, 2041 (1) : 309 - 309
[26] NivolumabImmune-mediated pericarditis, pericardial tamponade and thyroiditis: case report
Reactions Weekly, 2018, 1720 (1) : 194 - 194
[27] Ipilimumab/nivolumabImmune-mediated colitis and immune-mediated dermatitis: case report
Reactions Weekly, 2021, 1836 (1) : 435 - 435
[28] Ipilimumab/NivolumabImmune-mediated enteritis and off label use: case report
Reactions Weekly, 2024, 2036 (1) : 231 - 231
[29] Ipilimumab/nivolumabImmune-mediated hypothyroidism and immune-mediated hypophysitis: case report
Reactions Weekly, 2023, 1969 (1) : 201 - 201
[30] Ipilimumab/methylprednisolone/nivolumabImmune-mediated colitis and lack of efficacy: case report
Reactions Weekly, 2022, 1927 (1) : 304 - 304

← 1 2 3 4 5 →